Cosmetic Regulations In 2025: MoCRA, FDA Compliance & What Global Brands Must Know

The global cosmetic regulatory landscape has entered a transformative phase. With the full implementation of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), 2025 marks a critical compliance year for cosmetic manufacturers, importers, private-label owners, and global beauty brands operating in or exporting to the United States.

The U.S. FDA now exercises significantly expanded authority over cosmetic products and manufacturing operations. Mandatory facility registration, cosmetic product listing, adverse event reporting, safety substantiation, labeling modernization, and the upcoming cosmetic GMP (cGMP) framework are reshaping how cosmetic companies manage regulatory compliance.

For global brands, MoCRA compliance is no longer optional it is directly tied to market access, import eligibility, consumer trust, investor confidence, and long-term commercial sustainability.

This comprehensive guide by Maven Regulatory Solutions explains the strategic implications of MoCRA in 2025, outlines FDA enforcement expectations, and provides a practical compliance roadmap for cosmetic organizations navigating the evolving regulatory environment.

Understanding MoCRA & The FDA’s Expanded Cosmetic Authority

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) represents the most significant reform to U.S. cosmetic regulation since the Federal Food, Drug, and Cosmetic Act of 1938.

MoCRA significantly expands FDA oversight by granting authority to:

• Require mandatory facility registration 
• Enforce cosmetic product listing 
• Conduct facility inspections 
• Request safety substantiation records 
• Monitor serious adverse events 
• Mandate product recalls 
• Develop cosmetic GMP regulations 
• Strengthening traceability and recordkeeping 

The legislation fundamentally shifts cosmetic compliance from a largely voluntary system to a legally enforceable regulatory framework.

Why MoCRA Matters for Global Cosmetic Brands

The FDA’s strengthened oversight impacts virtually every stakeholder in the cosmetic supply chain, including:

• Cosmetic manufacturers 
• Contract manufacturing organizations (CMOs) 
• Importers 
• Private-label brands 
• Brand owners 
• Ingredient suppliers 
• Distributors 
• E-commerce cosmetic sellers 

Organizations must now proactively integrate regulatory compliance into their operational, manufacturing, labeling, pharmacovigilance, and quality management systems.

Key Strategic Priorities Under MoCRA

Key FDA Cosmetic Compliance Milestones For 2025

The FDA has already begun active implementation and enforcement activities under MoCRA.

Major Regulatory Deadlines

These timelines make 2025 a pivotal year for compliance readiness and operational adaptation.

Facility Registration Requirements Under MoCRA

Who Must Register?

Any facility engaged in manufacturing or processing cosmetic products for U.S. distribution may require FDA registration.

This includes:

• Domestic manufacturers 
• Foreign cosmetic facilities 
• Contract manufacturers 
• Private-label manufacturers 
• Import-focused production facilities 

Small and emerging cosmetic brands are generally not exempt from core registration obligations.

Registration Process

Facilities must submit registration information electronically using FDA systems, including:

• Facility identification details 
• Product categories manufactured 
• Ownership information 
• Contact details 
• U.S. Agent information (for foreign facilities) 

Ongoing Compliance Obligations

Risks Of Non-Compliance

Failure to register may result in:

• Import refusals 
• FDA warning letters 
• Inspection escalation 
• Product detention 
• Market access restrictions 

Cosmetic Product Listing Requirements

MoCRA now requires FDA cosmetic product listing for marketed products.

Required Listing Information

Manufacturers or Responsible Persons must provide:

• Product name 
• Cosmetic category 
• Ingredient listing 
• Responsible Person information 
• Product variants 
• Intended use 

Listings must accurately reflect current commercial formulations.

Lifecycle Management Considerations

Organizations must maintain dynamic compliance systems to manage:

Large global portfolios increasingly require centralized regulatory information management systems.

Adverse Event Reporting & Pharmacovigilance Obligations

One of the most significant changes under MoCRA is mandatory adverse event reporting.

15-Business-Day Reporting Requirement

Responsible Persons must report serious adverse events to the FDA within:

15 Business Days

of becoming aware of the event.

Serious Adverse Events May Include

• Hospitalization 
• Significant infection 
• Permanent impairment 
• Disfigurement 
• Life-threatening reactions 
• Serious allergic responses 

A copy of the product label must accompany each submission.

Required Documentation Systems

Companies should maintain:

• Consumer complaint handling systems 
• Investigation procedures 
• CAPA programs 
• Medical review processes 
• Complaint trend analysis 
• Long-term adverse event archives 

Cosmetic pharmacovigilance is becoming increasingly aligned with pharmaceutical-style safety monitoring systems.

Cosmetic GMP (cGMP) Requirements: Preparing for December 2025

MoCRA requires the FDA to finalize cosmetic Good Manufacturing Practices (cGMPs) by December 29, 2025.

Expected Areas Of FDA GMP Oversight

Strategic Preparation Steps

Manufacturers should be proactive:

• Conduct GMP gap assessments 
• Implement SOP frameworks 
• Strengthen supplier qualification programs 
• Establish deviation management systems 
• Train manufacturing personnel 
• Improve batch documentation practices 

Early readiness reduces operational disruption once final GMP rules become enforceable.

Labeling & Safety Substantiation Requirements

Mandatory Label Information

Cosmetic labels must now include:

• Responsible Person name 
• Physical business address 
• Domestic phone number or website 

Email-only contact information is insufficient under MoCRA.

Safety Substantiation Expectations

Brands must maintain adequate evidence supporting product safety.

Acceptable safety substantiation may include:

• Toxicological assessments 
• Ingredient safety reviews 
• Scientific literature 
• Product testing data 
• Supplier safety certifications 
• Stability data 

PFAS & Ingredient Scrutiny

The FDA continues active evaluation of:

PFAS (Per- and Polyfluoroalkyl Substances)

and other high-risk cosmetic ingredients.

Ingredient transparency expectations are expected to increase substantially beyond 2025.

FDA Inspection Authority & Enforcement Risk

The FDA now possesses expanded cosmetic inspection powers under MoCRA.

Inspection Readiness Requirements

Organizations should ensure:

• Immediate document accessibility 
• Trained inspection personnel 
• Complaint handling records 
• Product traceability systems 
• CAPA documentation 
• Supplier qualification evidence 

Potential Enforcement Actions

Regulatory enforcement activity is expected to intensify throughout 2025 and beyond.

Strategic Compliance Considerations for Global Brands

Key Areas Requiring Executive Attention

Manufacturers should proactively evaluate:

• Global portfolio registration accuracy 
• Cross-border supply chain traceability 
• Label harmonization strategies 
• Ingredient compliance monitoring 
• Adverse event escalation workflows 
• GMP modernization investments 
• Regulatory intelligence monitoring 

ESG & Sustainability Integration

Cosmetic compliance increasingly intersects with:

• ESG reporting 
• Sustainable ingredient sourcing 
• Packaging sustainability 
• Consumer transparency initiatives 
• Ethical supply chain expectations 

Organizations integrating sustainability and compliance strategies may gain significant competitive advantages.

Common Compliance Challenges Under MoCRA

Organizations frequently encounter challenges involving:

• Multi-market regulatory coordination 
• Facility registration management 
• Product listing complexity 
• Ingredient disclosure accuracy 
• Adverse event reporting workflows 
• GMP readiness gaps 
• Supplier documentation limitations 
• Rapid portfolio expansion 

Cross-functional regulatory governance is now essential.

Future Trends in Cosmetic Regulation

Emerging regulatory trends include:

• Increased FDA enforcement activity 
• Expansion of ingredient transparency requirements 
• Greater alignment with EU cosmetic regulations 
• Digital compliance reporting systems 
• Enhanced sustainability disclosures 
• Stricter PFAS Oversight 
• AI-enabled regulatory surveillance 
• Global harmonization initiatives 

The cosmetic industry is moving toward increasingly data-driven and risk-based regulatory oversight.

Quick Facts

• MoCRA represents the largest FDA cosmetic reform in decades 
• Facility registration and product listing are mandatory 
• Serious adverse events must be reported within 15 business days  
• Cosmetic GMP rules are expected by December 29, 2025 
• Foreign cosmetic facilities must designate U.S. Agents 
• Product safety substantiation is legally required 
• FDA inspection authority has expanded significantly 
• PFAS regulation remains an evolving enforcement priority 

Why Compliance Matters

Failure to comply with MoCRA may result in:

• FDA warning letters 
• Product recalls 
• Import alerts 
• Market access restrictions 
• Supply chain disruption 
• Increased legal exposure 
• Reputational damage 
• Consumer trust erosion 

A proactive regulatory strategy is now essential for commercial continuity and global competitiveness.

How Maven Regulatory Solutions Supports Cosmetic Brands

Our Services

• MoCRA compliance strategy 
• FDA cosmetic facility registration support 
• Cosmetic product listing management 
• Cosmetic GMP readiness assessments 
• Labeling compliance review 
• Safety substantiation consulting 
• Adverse event reporting systems 
• Regulatory gap assessments 
• Global cosmetic regulatory strategy 
• Import compliance support 

Why Choose Maven

• Deep FDA cosmetic regulatory expertise 
• Global cosmetic compliance experience 
• Integrated quality & regulatory approach 
• GMP implementation support 
• Risk-based compliance strategies 
• Up-to-date FDA regulatory intelligence 

Our approach helps organizations achieve:

• Faster regulatory alignment 
• Reduced enforcement risk 
• Sustainable compliance systems 
• Improved operational readiness 
• Long-term market continuity 

Need Support Navigating MoCRA & FDA Cosmetic Compliance?

Whether you are preparing for cosmetic GMP requirements, managing FDA registrations, implementing adverse event systems, or strengthening labeling compliance, Maven Regulatory Solutions can help simplify your regulatory pathway.

Contact Maven Regulatory Solutions For:

• MoCRA compliance strategy 
• FDA cosmetic registration support 
• Cosmetic GMP readiness 
• Labeling compliance assessments 
• Safety substantiation review 
• Adverse event reporting systems 
• Global Cosmetic Regulatory Consulting 
• Import compliance strategy 

Visit Maven Regulatory Solutions to connect with our cosmetic regulatory experts today.

Conclusion

MoCRA has fundamentally transformed cosmetic regulation in the United States. In 2025, cosmetic compliance is no longer simply an administrative obligation it is a strategic business requirement influencing market access, operational continuity, consumer confidence, and long-term brand growth.

Organizations that proactively invest in regulatory infrastructure, GMP readiness, safety substantiation, and lifecycle compliance management will be best positioned to succeed in the evolving FDA regulatory environment.

Maven Regulatory Solutions partners with cosmetic organizations worldwide to support sustainable compliance through strategic regulatory planning, FDA expertise, and operational regulatory excellence.

Frequently Asked Questions

Q1. Is MoCRA applicable to import cosmetics?

Yes. Foreign manufacturers exporting cosmetics to the U.S. must fully comply with MoCRA requirements, including facility registration and U.S. Agent designation.

Q2. Are small cosmetic brands exempt from FDA registration?

No. Most cosmetic businesses must comply with registration and listing obligations regardless of company size.

Q3. When will cosmetic GMP regulations become enforceable?

The FDA is expected to finalize cosmetic GMP regulations by December 29, 2025.

Q4. Do formulation changes require FDA listing updates?

Yes. Significant formulation or ingredient changes require product listing updates.

Q5. What is safety substantiation under MoCRA?

Safety substantiation refers to scientific evidence demonstrating that a cosmetic product is safe under intended conditions of use.

Q6. Can the FDA recall cosmetic products?

Yes. MoCRA grants the FDA mandatory recall authority for cosmetics posing health risks.

Q7. How can Maven support cosmetic manufacturers?

Maven provides regulatory strategy, FDA registration support, GMP readiness consulting, labeling review, and end-to-end cosmetic compliance solutions.